Defining and Targeting the Oncogenic Drivers of Neuroendocrine Prostate Cancer

Cancer Cell. 2016 Apr 11;29(4):431-432. doi: 10.1016/j.ccell.2016.03.023.

Abstract

In this issue of Cancer Cell, Lee and colleagues (2016) define the biologic role of MYCN in promoting prostate tumorigenesis and development of a neuroendocrine phenotype. This has important implications for the clinical management of neuroendocrine prostate cancer as Aurora A kinase inhibitors promoting N-Myc destabilization progress in the clinic.

Publication types

  • Comment

MeSH terms

  • Aurora Kinase A
  • Carcinoma, Neuroendocrine*
  • Cell Line, Tumor
  • Humans
  • Male
  • Prostatic Neoplasms / genetics*

Substances

  • Aurora Kinase A